Pay in 4 interest-free payments of $6.75 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
DPP-4 inhibitor impedes lipopolysaccharide-induced osteoclast formation and bone resorption in vivo
Conclusion BPC-157 sits in a research category where the preclinical evidence base is broad but human clinical data is thin
Based on the identification of CDK4 amplification and homologous recombination repair deficiency as prominent features of osteosarcoma, a MOF co-loaded with CDK4/6 inhibitors and PARP inhibitors was designed and coated with a bio-membrane targeting B7H3
& Lam, C
US$ 28.43
US$ 26.00
US$ 28.40
US$ 29.10
US$ 20.87
US$ 24.50
